The global lipids market is projected to register a substantial CAGR of 8.4% from 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030.
Market Segmentation:
Global Lipids Market, By Type (Natural Lipids and Synthetic Lipids), Lipid System (Neutral Lipids, Bacterial Lipids, Fluorescent Lipids, Bioactive Lipids, Polymerizable Lipids, Headgroup Modified Lipids, and Others), Delivery System (Liposomes, Solid Lipid Nanoparticles, Nanostructures Lipid Carrier, Niosomes, Transferosomes, and others), Source (Eggyolk, Soyabean, Non-GMO Soyabean, Purified Oils, Purified Fatty Acids, and Others), End User (Pharmaceutical Industries, Biotechnology Industries, Academic and Research Institutes, Cosmetic Industries, and Others), Distribution Channel (Direct Tender, Retail Sales and, Others), Country (U.S., Canada, Mexico, Germany, France, U.K, Italy, Spain, Netherland, Russia, Switzerland, Turkey, Rest of Europe, China, Japan, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, and Rest of Middle East and Africa) Industry Trends and Forecast to 2030.
Some of the major factors contributing to the growth of global lipids market are:
Growing healthcare expenditure
Improved diagnostic processes and techniques
Improved imaging techniques
Market Players:
The key market players in the global lipids market are listed below:
Alnylam Pharmaceutical, Inc.
Croda International Plc.
Moderna Inc.
BioNTech SE.
Pfizer Inc.
Evonik Industries AG
Lipoid GmbH
Matreya LLC
VAV Life Sciences Pvt Ltd.
Curia Global Inc.
Cargill, Incorporated
Gattefosse
CD Bioparticles
Merck KGaA
NOF EUROPE GmbH
ABITEC
Cayman Chemical
CordenPharma International
CHEMI S.p.A.
DSM
BASF SE
Tokyo Chemical Industry Co., Ltd.
ADMSIO
Stepan Company
Kerry
TABLE OF CONTENTS
1 INTRODUCTION 45
- 1.1 OBJECTIVES OF THE STUDY 45
- 1.2 MARKET DEFINITION 45
- 1.3 OVERVIEW OF GLOBAL LIPIDS MARKET 45
- 1.4 LIMITATIONS 47
- 1.5 MARKETS COVERED 47
2 MARKET SEGMENTATION 51
- 2.1 MARKETS COVERED 51
- 2.2 GEOGRAPHICAL SCOPE 52
- 2.3 YEARS CONSIDERED FOR THE STUDY 53
- 2.4 CURRENCY AND PRICING 53
- 2.5 DBMR TRIPOD DATA VALIDATION MODEL 54
- 2.6 MULTIVARIATE MODELLING 57
- 2.7 TYPE LIFELINE CURVE 57
- 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 58
- 2.9 DBMR MARKET POSITION GRID 59
- 2.10 MARKET END USER COVERAGE GRID 60
- 2.11 VENDOR SHARE ANALYSIS 61
- 2.12 SECONDARY SOURCES 62
- 2.13 ASSUMPTIONS 62
3 EXECUTIVE SUMMARY 63
4 PREMIUM INSIGHTS 66
- 4.1 PESTEL ANALYSIS 69
- 4.2 PORTER'S FIVE FORCES 70
- 4.3 MERGER AND ACQUISITION, GLOBAL LIPIDS MARKET 71
- 4.4 PATENT ANALYSIS, GLOBAL LIPIDS MARKET 72
- 4.5 DRUG TREATMENT RATE BY MATURED MARKETS 73
- 4.6 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATE 74
- 4.7 KEY PRICING STRATEGIES 75
- 4.8 KEY PATIENT ENROLLMENT STRATEGIES 76
- 4.9 PRICE ANALYSIS, GLOBAL LIPIDS MARKET 77
- 4.10 GLOBAL LIPIDS MARKET, CLINICAL TRIALS 79
- 4.11 GLOBAL LIPIDS MARKET, DISTRIBUTION OF PRODUCTS BY PHASE 80
- 4.12 GLOBAL LIPIDS MARKET, PIPELINE ANALYSIS 81
- 4.13 PHASE I CANDIDATES 81
- 4.14 PHASE I/II CANDIDATES 82
- 4.15 PHASE II CANDIDATES 83
- 4.16 PHASE III CANDIDATES 84
5 GLOBAL LIPIDS MARKET, REGULATORY FRAMEWORK 85
- 5.1 REGULATION IN THE U.S.: 85
- 5.2 REGULATION IN EUROPE: 86
6 MARKET OVERVIEW 87
- 6.1 DRIVERS 89
- 6.1.1 INCREASE IN THE PREVALENCE OF CHRONIC DISEASES 89
- 6.1.2 RISE IN DEMAND FOR LIPIDS IN FOOD AND BEVERAGE AS WELL AS THE COSMETIC INDUSTRY 89
- 6.1.3 INCREASE IN DRUG DEVELOPMENT 90
- 6.2 RESTRAINTS 90
- 6.2.1 HIGH COST OF LIPID SYNTHESIS AND INCREASING COST OF RAW MATERIALS 90
- 6.2.2 STRICT GOVERNMENT REGULATIONS 91
- 6.3 OPPORTUNITIES 92
- 6.3.1 RISE IN HEALTHCARE EXPENDITURE 92
- 6.3.2 STRATEGIC INITIATIVES BY MARKET PLAYERS 92
- 6.4 CHALLENGES 93
- 6.4.1 DIFFERENT MANUFACTURING CHALLENGES FOR LIPID NANOPARTICLE PRODUCTION 93
- 6.4.2 LACK OF HEALTHCARE FACILITIES IN EMERGING ECONOMIES 93
7 GLOBAL LIPIDS MARKET, BY TYPE 94
- 7.1 OVERVIEW 95
- 7.2 NATURAL LIPID 98
- 7.2.1 UNSATURATED PHOSPHOLIPID 98
- 7.2.2 HYDROGENATED PHOSPHOLIPID 99
- 7.2.3 SPHINGOMYELIN 99
- 7.2.4 GLYCEROLPHOSPHOCHOLINE 99
- 7.3 SYNTHETIC LIPID 99
- 7.3.1 PEGYLATED PHOSPHOLIPIDS 100
- 7.3.2 PHOSPHATIDYLSERINE 100
- 7.3.3 PHOSPHATIDYGLYCEROLS 100
- 7.3.4 PHOSPHATIDYLETHANOLAMINE 100
- 7.3.5 PHOSPHATIDYLCHOLINE 100
- 7.3.6 PHOSPHATIDIC ACIDS 100
8 GLOBAL LIPIDS MARKET, BY LIPID SYSTEMS 101
- 8.1 OVERVIEW 102
- 8.2 BIOACTIVE LIPIDS 105
- 8.2.1 PLANT LIPIDS 106
- 8.2.2 LIPID ACTIVATORS 106
- 8.2.3 LIPID INHIBITORS 106
- 8.2.4 AGONISTS 106
- 8.2.5 BIOACTIVE CERAMIDES 106
- 8.2.6 ACYL CARNITINE LIPIDS 106
- 8.2.7 ENDOCANNABINOIDS 107
- 8.2.8 LIPO-NUCLEOTIDES 107
- 8.2.9 LYSYL-PHOSPHATIDYLGLYCEROL 107
- 8.2.10 DIACYLGLYCEROL PYROPHOSPHATE (DGPP) 107
- 8.3 POLYMERIZABLE LIPIDS 107
- 8.3.1 FUNCTIONAL PEG LIPIDS 108
- 8.3.2 MPEG STEROLS 108
- 8.3.3 MPEG CERAMIDES 108
- 8.3.4 MPEG PHOSPHOLIPIDS 108
- 8.3.5 MPEG GLYCERIDES 108
- 8.4 FLUORESCENT LIPIDS 109
- 8.4.1 FLUORESCENT SPHINGOLIPIDS 110
- 8.4.2 FLUORESCENT GLYCEROLIPIDS 110
- 8.4.3 FLUORESCENT PEG LIPIDS 110
- 8.4.4 FLUORESCENT PHOSPHOLIPIDS 110
- 8.4.5 FLUORESCENT STEROLS 110
- 8.4.6 OTHERS 110
- 8.5 BACTERIAL LIPIDS 111
- 8.5.1 MYCOLIC LIPIDS 112
- 8.5.2 N-ACYLHOMOSERINE LIPIDS 112
- 8.5.3 BRANCHED LIPIDS 112
- 8.5.4 CYCLOPROPYL LIPIDS 112
- 8.6 NEUTRAL LIPIDS 112
- 8.6.1 PRENOLS 113
- 8.6.2 VERY LONG CHAIN FATTY ACIDS 113
- 8.6.3 GLYCERIDES 113
- 8.6.4 EICSANOIDS 113
- 8.6.5 OXYGENATED FATTY ACIDS 113
- 8.6.6 GLYCOSYLATED DIACYL GLYCEROLS 113
- 8.6.7 PROSTAGLANDINS 113
- 8.7 HEADGROUP MODIFIED LIPIDS 114
- 8.7.1 FUNCTIONAL LIPIDS 115
- 8.7.2 ANTIGENIC LIPIDS 115
- 8.7.3 GLYCOSYLATED LIPIDS 115
- 8.7.4 CHELATORS 115
- 8.7.5 ADHESIVE LIPIDS 115
- 8.7.6 SNAP-TAG REACTING LIPIDS 115
- 8.7.7 ALKYL PHOSPHATES 115
- 8.8 OTHERS 116
9 GLOBAL LIPIDS MARKET, BY DELIVERY SYSTEMS 117
- 9.1 OVERVIEW 118
- 9.2 LIPOSOMES 121
- 9.2.1 LIPOSOMES FOR DNA/RNA 122
- 9.2.1.1 DOTAP LIPOSOMES FOR DNA/RNA DELIVERY 122
- 9.2.1.2 DDAB LIPOSOMES FOR DNA/RNA DELIVERY 122
- 9.2.1.3 GL-67 LIPOSOMES FOR DNA/RNA DELIVERY 122
- 9.2.1.4 DC-CHOLESTEROL LIPOSOMES FOR DNA/RNA DELIVERY 122
- 9.2.1.5 DOTMA LIPOSOMES FOR DNA/RNA DELIVERY 123
- 9.2.1.6 DODAP LIPOSOMES FOR DNA/RNA DELIVERY 123
- 9.2.2 REACTIVE LIPOSOMES 123
- 9.2.2.1 SUCCINYL LIPOSOMES 123
- 9.2.2.2 DBCO LIPOSOMES 123
- 9.2.2.3 BIOTINYLATED LIPOSOMES 124
- 9.2.2.4 CARBOXYLIC ACID LIPOSOMES 124
- 9.2.2.5 AMINE LIPOSOMES 124
- 9.2.2.6 CYANUR LIPOSOMES 124
- 9.2.2.7 AZIDE LIPOSOMES 124
- 9.2.2.8 FOLATE LIPOSOMES 124
- 9.2.2.9 DODECANYL LIPOSOMES 124
- 9.2.2.10 NI REACTIVE LIPOSOMES 124
- 9.2.2.11 PDP LIPOSOMES 124
- 9.2.2.12 GLUTARYL LIPOSOMES 124
- 9.2.2.13 OTHERS 124
- 9.2.3 DRUG LOADED LIPOSOMES 125
- 9.2.4 PLAIN LIPOSOMES 125
- 9.2.4.1 CARDIOLIPIN LIPIDS LIPOSOMES 125
- 9.2.4.2 DOTAP LIPOSOMES 125
- 9.2.4.3 PHOSPHATIDYLSERINE LIPOSOMES 125
- 9.2.4.4 PHOSPHATIDYLCHOLINE LIPOSOMES 125
- 9.2.4.5 PHOSPHATIDYL GLYCEROL LIPOSOMES 125
- 9.2.4.6 OTHERS 126
- 9.3 SOLID LIPID NANOPARTICLES 126
- 9.4 NANOSTRUCTURES LIPID CARRIER 127
- 9.5 TRANSFEROSOMES 128
- 9.6 NIOSOMES 129
- 9.7 OTHERS 130
10 GLOBAL LIPIDS MARKET, BY SOURCE 131
- 10.1 OVERVIEW 132
- 10.2 PURIFIED FATTY ACIDS 135
- 10.3 PURIFIED OILS 136
- 10.4 EGG YOLK 137
- 10.5 SOYABEAN 138
- 10.6 NON-GMO SOYABEAN 139
- 10.7 OTHERS 140
11 GLOBAL LIPIDS MARKET, BY END USER 141
- 11.1 OVERVIEW 142
- 11.2 PHARMACEUTICAL INDUSTRIES 145
- 11.3 BIOTECHNOLOGY INDUSTRIES 146
- 11.4 COSMETIC INDUSTRIES 147
- 11.5 ACADEMIC AND RESEARCH INSTITUTES 147
- 11.6 OTHERS 148
12 GLOBAL LIPIDS MARKET, BY DISTRIBUTION CHANNEL 149
- 12.1 OVERVIEW 150
- 12.2 DIRECT TENDER 153
- 12.3 RETAIL SALES 154
- 12.4 OTHERS 155
13 GLOBAL LIPIDS MARKET, BY REGION 156
- 13.1 OVERVIEW 157
- 13.2 NORTH AMERICA 163
- 13.2.1 U.S. 175
- 13.2.2 CANADA 182
- 13.2.3 MEXICO 189
- 13.3 EUROPE 196
- 13.3.1 GERMANY 208
- 13.3.2 U.K. 215
- 13.3.3 ITALY 222
- 13.3.4 SPAIN 229
- 13.3.5 FRANCE 236
- 13.3.6 SWITZERLAND 243
- 13.3.7 BELGIUM 250
- 13.3.8 NETHERLANDS 257
- 13.3.9 RUSSIA 264
- 13.3.10 TURKEY 271
- 13.3.11 REST OF EUROPE 278
- 13.4 ASIA-PACIFIC 279
- 13.4.1 CHINA 291
- 13.4.2 JAPAN 298
- 13.4.3 SOUTH KOREA 305
- 13.4.4 INDIA 312
- 13.4.5 AUSTRALIA 319
- 13.4.6 SINGAPORE 326
- 13.4.7 THAILAND 333
- 13.4.8 MALAYSIA 340
- 13.4.9 INDONESIA 347
- 13.4.10 PHILIPPINES 354
- 13.4.11 REST OF ASIA PACIFIC 361
- 13.5 SOUTH AMERICA 362
- 13.5.1 BRAZIL 374
- 13.5.2 ARGENTINA 381
- 13.5.3 REST OF SOUTH AFRICA 388
- 13.6 MIDDLE EAST AND AFRICA 389
- 13.6.1 SOUTH AFRICA 401
- 13.6.2 SAUDI ARABIA 408
- 13.6.3 U.A.E. 415
- 13.6.4 EGYPT 422
- 13.6.5 ISRAEL 429
- 13.6.6 REST OF MIDDLE EAST AND AFRICA 436
14 GLOBAL LIPIDS MARKET: COMPANY LANDSCAPE 437
- 14.1 COMPANY SHARE ANALYSIS: GLOBAL 437
- 14.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 438
- 14.3 COMPANY SHARE ANALYSIS: EUROPE 439
- 14.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 440
15 SWOT ANALYSIS 441
16 COMPANY PROFILE 442
- 16.1 BIONTECH SE. 442
- 16.1.1 COMPANY SNAPSHOT 442
- 16.1.2 REVENUE ANALYSIS 443
- 16.1.3 COMPANY SHARE ANALYSIS 443
- 16.1.4 PRODUCT PORTFOLIO 443
- 16.1.5 RECENT DEVELOPMENT 444
- 16.2 MODERNA, INC. 445
- 16.2.1 COMPANY SNAPSHOT 445
- 16.2.2 REVENUE ANALYSIS 445
- 16.2.3 COMPANY SHARE ANALYSIS 446
- 16.2.4 PRODUCT PORTFOLIO 446
- 16.2.5 RECENT DEVELOPMENTS 446
- 16.3 PFIZER INC. 447
- 16.3.1 COMPANY SNAPSHOT 447
- 16.3.2 REVENUE ANALYSIS 447
- 16.3.3 COMPANY SHARE ANALYSIS 448
- 16.3.4 PRODUCT PORTFOLIO 448
- 16.3.5 RECENT DEVELOPMENTS 448
- 16.4 CARGILL, INCORPORATED. 449
- 16.4.1 COMPANY SNAPSHOT 449
- 16.4.2 COMPANY SHARE ANALYSIS 449
- 16.4.3 PRODUCT PORTFOLIO 449
- 16.4.4 RECENT DEVELOPMENTS 449
- 16.5 KERRY. 450
- 16.5.1 COMPANY SNAPSHOT 450
- 16.5.2 COMPANY SHARE ANALYSIS 450
- 16.5.3 PRODUCT PORTFOLIO 451
- 16.5.4 RECENT DEVELOPMENTS 451